X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. 

Biotechnology

X4 Pharmaceuticals

Paula Ragan

Christophe Arbet-Engels

Mary DiBiase

Mark Baldry

Adam Mostafa

Art Taveras

Leadership Team

Clinical Operations and Quality Management

Marketing and Commercial Strategy

Finance and Accounting

Research and Development

��

Teams at X4 Pharmaceuticals

Leadership Team

Clinical Operations and Quality Management

Marketing and Commercial Strategy

Finance and Accounting

Research and Development

��������

Teams at X4 Pharmaceuticals

Leadership Team

Clinical Operations and Quality Management

Marketing and Commercial Strategy

Finance and Accounting

Research and Development

��